
Cognitive Synergy: Advancing neuroscience research for Alzheimer's treatment, fostering collaboration, and educating communities.
Cognitive Synergy is a research-based biopharmaceutical company dedicated to advancing neuroscience research, particularly in the treatment and prevention of Alzheimer's disease and other neurologic disorders. The company focuses on discovering and developing innovative medicines through cutting-edge technology and collaborative research. Cognitive Synergy aims to educate the community and serve as a resource by connecting patients, families, research centers, universities, and pharmaceutical companies.
Cognitive Synergy has made significant strides in the field of neurodegenerative disease research, contributing to the scientific understanding and potential treatment options for conditions like Alzheimer's. The company's collaborative approach has fostered partnerships with leading research institutions and pharmaceutical companies, enhancing its impact on the medical community. Through its innovative research and commitment to education, Cognitive Synergy continues to play a crucial role in the fight against neurologic disorders.

NeuroCog Trials

Neuraly
neuralymed.com

NeuroX1
neurox1.com

NeuroGenetic Pharmaceuticals

Intellect Neurosciences

Cajal Neuroscience
cajalneuro.com

AivoCode
aivocode.com

Synchroneuron

Neurovia

Cognito Therapeutics
cognitotx.com

Oscillo Biosciences

BioHealthonomics

Neurotrack
neurotrack.com

Alto Neuroscience

CognitiveCare
cognitivecare.com
Companies similar to Cognitive Synergy include NeuroCog Trials, Neuraly, NeuroX1 and NeuroGenetic Pharmaceuticals.
Cognitive Synergy was founded in 2017.
Cognitive Synergy's headquarters is located in California, US.
Cognitive Synergy's most recent funding round was for $1.8M (USD) in January 2018.
As of Jan 19, 2018, Cognitive Synergy has raised a total of $1.8M (USD).
Cognitive Synergy has 30 employees as of Feb 4, 2024.